GlassScriptPhysician profile
Lindsey A Lee
NPI 1891207023
$2,682.44
in general payments reported to CMS, 2019-2025
31 companies · $956 in 2025
The $956 reported for 2025 was more than what 84% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $434 · 2022: $280 · 2023: $308 · 2024: $704 · 2025: $956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,968.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $556.31 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $319.22 | 2021-2025 | |
| Harmony Biosciences LLC | $228.87 | 2024-2025 | |
| Lilly USA, LLC | $150.50 | 2021-2025 | Emgality, Amyvid, Reyvow |
| Procept Biorobotics Corporation | $144.45 | 2025 | |
| Axsome Therapeutics, INC. | $129.79 | 2023-2025 | Sunosi, Symbravo |
| Pfizer INC. | $116.81 | 2021-2025 | |
| Lundbeck LLC | $104.18 | 2023-2025 | Vyepti |
| Collegium Pharmaceutical, INC. | $98.76 | 2021 | |
| Merz Pharmaceuticals, LLC | $96.49 | 2024-2025 | Inbrija, Xeomin, Ampyra |
| Avadel Cns Pharmaceuticals, LLC | $86.08 | 2024-2025 | Lumryz |
| Almatica Pharma LLC | $71.70 | 2021 | |
| Eisai INC. | $64.21 | 2021-2025 | |
| Argenx US, INC. | $56.15 | 2023-2024 | Vyvgart Hytrulo |
| Idorsia Pharmaceuticals US INC | $48.93 | 2025 | Quviviq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $46.87 | 2021 | |
| Revance Therapeutics, INC. | $38.83 | 2024 | Daxxify |
| Inspire Medical Systems, INC. | $33.16 | 2025 | Inspire |
| Alexion Pharmaceuticals, INC. | $29.38 | 2022 | |
| Tanabe Pharma America, INC. | $29.23 | 2025 | Radicava |
| Zoll Respicardia, INC. | $28.28 | 2023 | Remede System |
| Tg Therapeutics, INC. | $27.55 | 2025 | |
| Noctrix Health, INC. | $26.08 | 2025 | Nidra |
| Genentech USA, INC. | $24.35 | 2025 | Ocrevus Zunovo |
| Horizon Therapeutics Plc | $23.50 | 2021 | |
| Nevro Corp. | $22.38 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.96 | 2022 | |
| Redhill Biopharma INC. | $17.02 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $17.02 | 2024 | Dysport |
| Scilex Pharmaceuticals INC. | $14.01 | 2021 | |
| Si-Bone, INC. | $13.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.